GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Synlab AG (FRA:SYAB) » Definitions » Debt-to-EBITDA

Synlab AG (FRA:SYAB) Debt-to-EBITDA : 2.67 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Synlab AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Synlab AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €158 Mil. Synlab AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1,388 Mil. Synlab AG's annualized EBITDA for the quarter that ended in Mar. 2024 was €580 Mil. Synlab AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.67.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Synlab AG's Debt-to-EBITDA or its related term are showing as below:

FRA:SYAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.69   Med: 2.5   Max: 4.87
Current: 2.53

During the past 4 years, the highest Debt-to-EBITDA Ratio of Synlab AG was 4.87. The lowest was 1.69. And the median was 2.50.

FRA:SYAB's Debt-to-EBITDA is ranked worse than
62.75% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs FRA:SYAB: 2.53

Synlab AG Debt-to-EBITDA Historical Data

The historical data trend for Synlab AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlab AG Debt-to-EBITDA Chart

Synlab AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
4.87 1.69 2.46 2.54

Synlab AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 3.74 1.65 5.59 2.67

Competitive Comparison of Synlab AG's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Synlab AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlab AG's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Synlab AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Synlab AG's Debt-to-EBITDA falls into.



Synlab AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Synlab AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(157.269 + 1402.768) / 614.311
=2.54

Synlab AG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(157.729 + 1387.795) / 579.912
=2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Synlab AG  (FRA:SYAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Synlab AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Synlab AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlab AG (FRA:SYAB) Business Description

Traded in Other Exchanges
Address
Moosacher Strasse 88, Augsburg, BY, DEU, 80809
Synlab AG is a medical diagnostics services provider in Europe. It offers a range of medical diagnostic services for practising doctors, clinics, and patients. Its geographical segments include France; Germany; South and North and East. The company derives a majority of revenue from the North and East.

Synlab AG (FRA:SYAB) Headlines

No Headlines